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EPIDEMIOLOGY
Thyroid Cancer and Nonsteroidal
Anti-Inflammatory Drug Use:
A Pooled Analysis of Patients Older Than 40 Years of Age
Dhaval Patel,1 Cari M. Kitahara,2 Yikyung Park,3,4 Linda M. Liao,4 Martha Linet,4
Electron Kebebew,1 and Naris Nilubol1
Background: Cyclooxygenase (COX-2) has been associated with tumor growth and metastasis in several cancers,
including thyroid cancer. For this reason, several investigators have studied COX-2 inhibitors in preclinical
models of thyroid cancer and found antineoplastic effects. Thus, the primary aim of this study was to assess if
the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced incidence of thyroid
cancer. A second aim of the study was to determine additional risk or protective factors for thyroid cancer.
Methods: Three large prospective population-based studies (the NIH-AARP Diet and Health Study; the Prostate,
Lung, Colorectal and Ovarian Cancer Screening Trial; and the U.S. Radiologic Technologists Study) were pooled
to investigate the association between self-reported frequency of aspirin and nonaspirin NSAID use one year prior
to baseline (no use, £2/week, >2–6/week, and ‡7/week) and subsequent risk of thyroid cancer. A Cox regression
proportional hazard model was used to estimate aggregated hazard ratios (HR) adjusted for cohort, sex, race/
ethnicity, weight, smoking status, and alcohol intake.
Results: There were 388,577 participants in the pooled cohort, with 481 cases of thyroid cancer. No significant
risk reduction was observed with regular use of nonaspirin NSAIDs (HR= 1.14 [confidence interval (CI) 0.84–
1.55]), and/or regular use of aspirin (HR= 1.06 [CI 0.82–1.39]). The multivariate regression analysis confirmed as
previously reported in the literature that female sex, obesity class I (body mass index [BMI]= 30–34.99 kg/m2),
and obesity class II (BMI= 35–35.99 kg/m2) were independently associated with an increased thyroid cancer risk.
Current smoking status and moderate and excessive alcohol use were also confirmed as independent risk factors
associated with a reduced thyroid cancer risk.
Conclusions: Neither nonaspirin NSAIDs nor aspirin use is associated with a reduced risk of thyroid cancer.
Women and obesity are associated with an increased risk of thyroid cancer, whereas smoking and alcohol use are
associated with decreased risk of thyroid cancer.
Introduction
The incidence of thyroid cancer, the most commonendocrine malignancy, has been increasing over the past
three decades. Between 1995 and 2005, the incidence of
thyroid cancer has increased by 98% in the United States (1).
As the incidence of thyroid cancer rises, it is important to
determine what preventive measures and risk-reduction ap-
proaches could be utilized to reduce thyroid cancer–related
morbidity and mortality, as well as the cost of care (2).
Cyclooxygenase-2 (COX-2) has been closely associated
with tumor growth and metastasis in a number of cancers
such as lung, breast, colorectal, and cervical cancer (3,4).
Patients with chronic lymphocytic thyroiditis were three
times more likely to have thyroid cancer, suggesting an as-
sociation between chronic inflammation and cancer devel-
opment (5,6). Overexpression of COX-2 has been observed
in thyroid follicular cells of patients with Hashimoto’s thy-
roiditis but not in normal thyroid or multinodular goiter tissue
(7,8). Several studies have demonstrated an overexpression
of COX-2 in papillary thyroid cancer (PTC) compared with
normal thyroid and multinodular goiter tissue (7,9,10).
In addition, the expression of COX-2 is associated with
older age, lymph node metastasis, and advanced stage in
patients with thyroid cancer (11,12). In vitro studies of thy-
roid cancer cell lines have shown that a selective inhibitor of
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COX-2, NS-398, can inhibit proliferation (13), and reduce
cellular migration and invasion (14). In esophageal cancer,
COX-2 expression has also been shown to be associated with
anti-apoptosis (15). These findings suggest a role of COX-2
in thyroid cancer development, and the potential of COX-2 as
a chemopreventive and therapeutic target. This approach has
been studied most notably in colorectal cancer. Chan et al.
analyzed a large prospective cohort study of 82,911 women
enrolled in the Nurses’ Health Study and reported a multi-
variate relative risk (RR) of 0.77 [confidence interval (CI)
0.67–0.88] among women with regular long-term aspirin use.
The use of aspirin and the multivariate RR was also found to
be dose dependent, and a similar trend was seen for NSAIDs
as well (16). Given the findings of in vitro studies and the
promising results of this study in colorectal cancer, aspirin
and NSAID use may reduce thyroid cancer incidence.
While the evidence strongly supports the chemopreven-
tive effect of NSAIDs in colorectal cancer (17), there is no
population-based study that addresses whether NSAIDs may
reduce the risk of thyroid cancer. It was hypothesized that the
incidence of thyroid cancer would be lower in individuals
taking NSAIDs. Therefore, the primary objective of this study
was to evaluate whether NSAID use reduces the risk of thy-
roid cancer in a large prospective population-based cohort.
Materials and Methods
Data sources
The data source consisted of three National Cancer In-
stitute (NCI) cohorts: (i) the National Institutes of Health-the
American Association of Retired Persons Diet and Health
Study (NIH-AARP); (ii) the Prostate, Lung, Colorectal and
Ovarian (PLCO); and (iii) the U.S. Radiologic Technologist
(USRT) Study. Each cohort met the following criterion: in-
dividual assessment of aspirin and nonaspirin NSAID use
within a similar time frame. Each cohort had individual
questions for the use of aspirin and nonaspirin NSAID use.
The three studies all had Institution Review Board approval
at the National Institutes of Health.
NIH-AARP Study. NIH-AARP, initiated in 1995–1996,
is a prospective cohort study examining the diet and lifestyle
factors of AARPmembers aged 50–71 years in six U.S. states
(California, Florida, Louisiana, New Jersey, North Carolina,
and Pennsylvania) and two metropolitan areas (Atlanta,
Georgia, and Detroit, Michigan). A self-administered base-
line questionnaire was mailed to 3.5 million members
of AARP aged 50–71 years in 1995–1996 and was returned
by 617,119 individuals (17.6%) (18). In 1996–1997, a sec-
ond questionnaire containing information on NSAID use was
completed by 334,908 participants. The study follow-up
period was from 1996 to 2003.
PLCO Cancer Screening Trial. PLCO, a multicenter trial,
evaluated the effectiveness of prostate, lung, colorectal, and
ovarian cancer screening with respect to disease-specific mor-
tality (19,20). Between October 1993 and July 2001, 154,952
subjects (49.5% men) aged 55–74 years were enrolled at 10
U.S. screening centers (Washington, DC; Detroit, Michigan;
Salt Lake City, Utah; Denver, Colorado; Honolulu, Hawaii;
Minneapolis, Minnesota; Marshfield, Wisconsin; Pittsburgh,
Pennsylvania; St. Louis,Missouri; andBirmingham,Alabama).
At the initial screening, a questionnaire (completed by
96.8% of participants) was administered that included items
about NSAID use. The study follow-up period was from
1993 to 2005.
USRT Study. USRT, a prospective cohort study, was
designed to evaluate the health history of radiologic tech-
nologists who had been certified for at least two years by the
American Registry of Radiologic Technologists between
1926 and 1980 (21,22). From 1994 to 1998, a questionnaire
was sent to all living individuals (126,628 participants),
which ascertained NSAID use. The questionnaire was re-
turned by 90,972 participants (71.8%). The study follow-up
period was from 1994 to 2004.
Thyroid cancer case ascertainment
The pooled population consisted of 388,577 individuals,
with 481 individuals (163 male) with thyroid cancer, as as-
certained by follow-up questionnaires for NIH-AARP,
PLCO, and USRT. Screening protocols for thyroid cancer
were not instituted in any of the three pooled protocols.
Assessment of NSAID use and aspirin use
The frequency of NSAID and aspirin use was ascertained
by analyzing data from self-administered questionnaires.
NIH-AARP and USRT questionnaires investigated aspirin
and general nonaspirin NSAID use (USRT: Ibuprofen, Motrin,
Naprosyn,Advil;NIH-AARP:generic ibuprofen,Advil,Nuprin,
Motrin, Aleve, Orudis, Ketoprofen, Naprosyn, Anaprox, Fel-
dene, Piroxicam, Clinoril, Sulindac, Indocin, Indomethacin,
Relafen, Nalfon, Nambumetone, Fenoprofen). PLCO inves-
tigated specifically aspirin- and ibuprofen-containingproducts
(Advil, Nuprin, Motrin, etc.). Participants were advised to not
include Tylenol or other pain relievers in their reports. Four
categories for frequency of NSAID and aspirin use within the
past 12 months were created based on previous literature and
analysis (23): no use (referent), no regular use (£2 times/
week), regular use less than daily (>2–6 times/week), and
regular daily use (‡7 times/week). The total duration of
NSAID or aspirin use was not captured in any cohort. Non-
aspirin NSAID and aspirin use were both included as inde-
pendent variables in the multivariate analysis.
Covariate information
All of the studies collected information regarding sex, race/
ethnicity, weight and height, smoking status, and alcohol sta-
tus. In order to assess whether the cohorts were comparable
and appropriate to be pooled, a hazard ratio (HR) of hetero-
geneity between studies was calculated. The HRs of hetero-
geneity between studies were assessed using the I2 index and
the Mantel–Haenszel test for heterogeneity (24,25).
Statistical methods
A Cox proportional hazard model was used to calculate
study-specific hazard ratios and confidence intervals for the
association of aspirin and NSAID use with thyroid cancer risk
with age as a time metric. Follow-up started at age at base-
line, which was defined as the time when NSAID exposure
was recorded. The follow-up ended at age at thyroid cancer
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diagnosis or age at censoring, which included diagnosis of
any other cancer, death, or the end of the study.
The three cohorts were aggregated into one pooled cohort.
Cohort-specific confounding variables were included in the
final model. The NIH-AARP cohort assessed smoking status
and smoking intensity by measuring cigarettes per day (never
use, former use of 1–20, former use of 21–40, former use of
‡41, current use of 1–20, current use of 21–40, current use of
‡41), race/ethnicity (white, other), body mass index (BMI;
18.2 £ 25 kg/m2, 25 £ 30 kg/m2, and ‡30 kg/m2), alcohol use
(g), and sex. The PLCO and USRT cohort assessed smoking
status (nonsmoker, former, current), race/ethnicity (white,
other), BMI, alcohol use (g), and sex.
Confounding variables were homogenized between the
studies by creating common variables: smoking (nonsmoker,
former, current), race/ethnicity (white, other), BMI (<25 kg/m2,
25–29.99kg/m2, 30–34.99 kg/m2, and >35 kg/m2), and alcohol
status (nondrinker, moderate <14 g, heavy >14 g). Additional
analyses assessing thyroid pathology by histologic subtype
were not completed given that the number of patients with
thyroid cancer incidence was low. Analyses were stratified by
sex, smoking status, alcohol status, and BMI.
Results
There were 388,577 individuals (200,601 male) in the
pooled cohort, with 481 cases of all subtypes of thyroid
cancer (163 male). A total of 4,302,158.84 person-years were
accrued in the cohort analyzed. Characteristics of thyroid
cancer incidence, NSAID use, and aspirin use are summa-
rized in Table 1. Selected demographic characteristics of the
cohort are summarized in Table 2. Heterogeneity of the data
due to cohort variability was assessed and shown to be similar
(Fig. 1).
No significant risk reduction in thyroid cancer incidence
was observed with nonaspirin NSAIDs and/or aspirin use
(Table 3). The independent factors (Table 4) associated with
increased thyroid cancer risk confirmed by a multivariate
analysis included female sex (HR 1.71 [CI 1.40–2.10],
p < 0.001), obesity class I (BMI 30–34.99 kg/m2; HR 1.41
[CI 1.08–1.84], p = 0.010), and obesity class II (BMI
35–35.99 kg/m2; HR 1.69 [CI 1.21–2.36], p = 0.002). As
previously documented in the literature, current smoking
status and moderate and excessive alcohol use was associated
with a reduced risk compared to nondrinkers (HR 0.65 [CI
0.46–0.92], p = 0.015; HR 0.78 [CI 0.63–0.97], p = 0.024; HR
0.68 [CI 0.50–0.93], respectively). USRT cohort affiliation
was associated with an increased risk of thyroid cancer (HR
2.21 [CI 1.78–2.75], p < 0.001).
Subanalysis of risk factors did not show any lower risk of
thyroid cancer with the consumption of either aspirin or
NSAID. Given the relatively low incidence of thyroid cancer,
a subtype analysis was not sufficiently powered and not
evaluated. Data on the type of thyroid cancer and extent of
disease were also not available.
Discussion
The current study is the largest prospective multicohort
analysis evaluating the role of NSAID use and risk of thyroid
cancer. This study shows that the use of nonaspirin NSAID
or aspirin was not associated with a reduced incidence of
thyroid cancer. The pooled analysis confirms the protective
association of thyroid cancer incidence and smoking and
alcohol use, and the higher risk of thyroid cancer associated
with obesity and female sex.
Tissue analysis of thyroid cancer has shown that COX-2
expression is upregulated in patients with thyroid cancer
compared with adjacent normal thyroid tissue (10), and these
findings were validated with immunohistochemistry findings
showing COX-2 expression to be higher in patients with
PTC (26). Furthermore, chronic inflammation with increased
expression of COX-2 has been associated with cancer (27)
and PTC (5,6). Thus, it was postulated that NSAID use could
potentially reduce inflammation and reduce the risk of can-
cer, as demonstrated in colorectal cancer (16,28). Therefore,
Table 1. Characteristics of the Cohort Studies Included in the Multicohort Analysis of Aspirin


































Overall 1993–2005 388,577 481 61.3 (55.7–66.0) 33.8 30.4 13.4 22.4 45.7 33.8 10.9 9.6
Men 200,764 163 62.4 (57.4–66.7) 26.0 29.5 15.3 29.2 50.2 31.9 10.3 7.7
Women 187,813 318 60.0 (53.5–65.4) 42.1 31.3 11.4 15.2 41.0 35.8 11.5 11.7
NIH-AARP 1996–2003 269,553 292 62.8 (58.0–66.7) 26.5 31.6 16.9 25.0 43.3 33.2 13.4 10.0
Men 157,880 130 63.1 (58.2–66.8) 21.2 31.0 17.5 30.3 46.0 34.1 12.0 7.9
Women 111,673 162 62.5 (57.7–66.5) 34.0 32.4 16.1 17.5 39.5 32.0 15.3 13.1
PLCO 1993–2005 58,433 56 62.0 (58.0–67.0) 51.2 13.8 8.5 26.5 70.9 13.7 5.6 9.7
Men 29,314 16 62.0 (58.0–67.0) 46.1 14.0 9.1 30.8 75.4 12.5 4.5 7.5
Women 29,119 40 62.0 (58.0–67.0) 56.3 13.6 7.8 22.3 66.4 15.0 6.7 11.9
USRT 1994–2004 60,591 133 45.5 (41.4–51.7) 49.4 41.0 2.6 7.0 32.1 55.4 5.0 7.4
Men 13,570 17 47.6 (43.2–54.6) 38.7 46.0 3.1 12.2 43.9 47.5 3.1 5.5
Women 47,021 116 44.8 (40.5–51.3) 52.6 39.5 2.4 5.5 28.8 57.7 5.5 8.0
NSAIDs, nonsteroidal anti-inflammatory drugs; NIH-AARP, the National Institutes of Health-the American Association of Retired
Persons Diet and Health Study; PLCO, the Prostate, Lung, Colorectal and Ovarian; USRT, the U.S. Radiologic Technologist.






































































































































































































































































































































































































































































































































































































































































































NSAID use could potentially reduce the risk of thyroid
cancer, which has financial and health-related consequences.
However, the present analysis did not reveal a reduced risk of
thyroid cancer with NSAID use in a population-based cohort
study. This may be due to many factors including an older
median age of the cohort, short duration of known NSAID
use, an insufficiently large enough study cohort given the low
incidence of thyroid cancer in these three pooled cohorts, and
relatively short duration of follow-up period. In the Nurses’
Health Study, Chan et al. did not see a relative risk reduction
of colorectal cancer incidence until patients were ingesting
aspirin or NSAIDs for at least a decade (16). The lack of
screening and the indolent natural history of thyroid cancer
may have confounded the results.
The increasing incidence of thyroid cancer has been as-
sociated with the detection of occult disease by numerous
authors. Udelsman et al. showed that the incidence rates were
significantly correlated with the density of endocrinologists
and the employment of cervical ultrasonography (29). Access
to care is associated with the incidence of PTC, as docu-
mented by Morris et al. in an analysis of the Surveillance,
Epidemiology, and End Results (SEER) database. In that
study, thyroid cancer incidence was significantly higher in
those over older than 65 years of age (annual percentage
change 8.8%) compared with those younger than 65 (annual
percentage change 6.4%) who do not have universal health-
care (30). Increasing access to healthcare may explain the
negative association with obesity. Obesity may be a surrogate
for increased use of healthcare resulting in an increased in-
cidence of thyroid cancer due to increased imaging use.
Morbidly obese patients have an 81% greater per capita
healthcare expenditure compared with normal-weight adults.
Among the reasons for increased expenditures, morbidly
obese adults had increased office-based visits and outpatient
hospital care (31). Likewise, smoking and alcohol may be
associated with a lowered incidence by a lower healthcare
access or use by that subset of patients. The lack of associ-
ation between NSAID use and thyroid cancer incidence
Table 3. Thyroid Cancer Risk and Use of Nonaspirin NSAIDs or Aspirin Among Men and Women in a Pooled
Analysis, NIH-AARP, PLCO, USRT
Overall Male Female
No. of cases HR 95% CI No. of cases HR 95% CI No. of cases HR 95% CI
Nonaspirin NSAIDs
No use 190 1.00 Ref 76 1.00 Ref 114 1.00 Ref
Nonregular 184 1.11 [0.89–1.37] 58 1.11 [0.78–1.59] 126 1.11 [0.85–1.45]
>2–6/week 54 1.10 [0.81–1.50] 17 1.02 [0.59–1.74] 37 1.16 [0.80–1.70]
‡7/week 53 1.14 [0.84–1.55] 12 0.91 [0.49–1.86] 41 1.26 [0.88–1.81]
Aspirin
No use 175 1.00 Ref 38 1.00 Ref 137 1.00 Ref
Nonregular 152 1.03 [0.83–1.29] 47 1.04 [0.67–1.60] 105 1.05 [0.81–1.36]
>2–6/week 64 1.20 [0.89–1.61] 25 1.12 [0.67–1.88] 39 1.28 [0.88–1.84]
‡7/week 90 1.06 [0.82–1.39] 53 1.25 [0.82–1.92] 37 0.88 [0.61–1.28]
HR, hazard ratio; CI, confidence interval.
FIG. 1. Forest plot of hazard ra-
tios separated by cohorts for both
nonaspirin nonsteroidal anti-
inflammatory drugs and aspirin
use. P-heterogeneity scores calcu-
lated to assess for cohort hetero-
geneity.
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might be explained by the presence of these confounding
factors. Nevertheless, the protective effects of smoking and
alcohol have to be weighed against the well-documented
known associated diseases, especially given the low mor-
bidity of thyroid cancer and excellent prognosis for early
stage disease.
Radiation exposure may be a confounding variable, since
the USRT cohort was included in this pooled analysis.
However, an analysis of these patients with occupational
radiation exposure has shown that total duration of occupa-
tion, employment below the age of 20, and years performing
diagnostic, therapeutic, and nuclear medicine procedures was
not associated with thyroid cancer incidence (32). The USRT
cohort has also been compared to age-specific, sex-specific,
and race-specific matched individuals in the SEER program.
The incidence of thyroid cancer is increased, but has been
attributed to this population having increased access to
imaging studies. An analysis showed that the frequency of
thyroid tumors £1 cm was twice as high in the USRT co-
hort (30% vs. 15%) compared with data obtained from the
SEER tumor registries. Furthermore, larger thyroid tumors
(1.5–2.5 cm) were found in 19% of participants in the USRT
cohort compared with 28% of registrants in the SEER data-
base (21). Therefore, occupational radiation exposure in the
USRT cohort was unlikely to have compromised the pooled
analysis results.
In summary, the use of NSAIDs was not associated with a
reduced risk of thyroid cancer. The data analysis confirms, as
previously reported in the literature, that obese patients have
a higher risk of thyroid cancer, and that current smoking and
moderate alcohol use are associated with a lower risk of
thyroid cancer. Therefore, contrary to the chemopreventive
effects of NSAIDs in colorectal cancer, the present analysis
does not support the use of NSAIDs to reduce the risk of
thyroid cancer.
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